share_log

Nasdaq Hearings Panel Granted Alzamend's Request To Continue Its Listing, Subject To Alzamend Demonstrating Compliance, On Or Before September 23, 2024

Benzinga ·  May 22 08:09

Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), announced today that the Nasdaq Hearings Panel ("Panel") granted Alzamend's request to continue its listing on The Nasdaq Capital Market ("Nasdaq"), subject to Alzamend demonstrating compliance, on or before September 23, 2024, with Listing Rule 5550(b)(1), which requires stockholder equity of at least $2.5 million (the "Stockholder Equity Rule"), and satisfying all applicable requirements for continued listing on Nasdaq.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment